India Caps Trade Margins at 30% on 137 Anti-Cancer Drugs, Prices to Fall Up to 70%
India's National Pharmaceutical Pricing Authority (NPPA) has capped trade margins at 30% for 137 non-scheduled anti-cancer drugs, effective November 9, 2026. This measure aims to reduce maximum retail prices by up to 70%, improving affordability and access to cancer treatments, including immunotherapies and targeted therapies. The list, recommended by an expert committee under the Directorate General of Health Services, will be updated periodically. Manufacturers, retailers, and hospitals must comply with revised pricing and display updated rates, with enforcement by state drug controllers.
First-hand measurement across 15 sources
We measured how 15 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (67/100). Lens Score 57/100.
Outlets measured: thehitavadacom, timesnow, thestatesman, freepressjournal, economictimes, hindustantimes, indianexpress, theprint, and 7 more. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment ranged widely across outlets — from 32/100 to 75/100 — a sign the coverage itself was contested, not just reported.
Coverage timeline
moneycontrol broke this story on 17 Oct, 03:29 pm. Other outlets followed.